Nilotinib is a potent DDR1 inhibitor with evidence from several clinical investigations for NDDs, including AD, PD, and HD (Pagan et al., 2020; Turner et al., 2020; Fowler et al., 2021; Anderson et al., 2022; Stevenson et al., 2023), showing nilotinib effects on autophagy, blood vessels and inflammation and subsequent effects on cognition and long-term motor stabilization. The gene discussed is DDR1; the disease is Parkinson disease.